Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gynecologic 5Plasma cell 1Lymphoid 1Breast 1

Conditions

Ovarian Neoplasms 5

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × TER 286 × Gynecologic × Clear all
NCT00350948 2013-11-27

ASSIST-5

Telik

Phase 3 Terminated
244 enrolled
Gynecologic

Ovarian Neoplasms

NCT00102973 2012-05-31

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 3 Completed
244 enrolled
Gynecologic

Ovarian Neoplasms

NCT00038428 2011-07-25

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Telik

Phase 2 Completed
40 enrolled
Gynecologic

Ovarian Neoplasms

NCT00051948 2011-07-25

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

NCT00052065 2011-07-25

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡